BIOGEN INC.
BIIB US09062X1037
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1% | 13% | -5% | -43% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Singhal Priya SR OFF |
133.55 USD |
517 Sold |
69,045 USD |
29/08/2025 | 02/09/2025 |
| Izzar Rachid SR OFF |
135.00 USD |
2,223 Sold |
300,105 USD |
08/07/2025 | 08/07/2025 |
| Singhal Priya SR OFF |
126.25 USD |
3,806 Sold |
480,508 USD |
19/05/2025 | 19/05/2025 |
| Dorsa Caroline |
122.72 USD |
1,235 Bought |
151,559 USD |
02/05/2025 | 02/05/2025 |
| Dorsa Caroline |
122.72 USD |
1,235 Bought |
151,559 USD |
02/05/2025 | 02/05/2025 |
| Sherwin Stephen A |
150.02 USD |
8,760 Sold |
1,314,142 USD |
07/03/2025 | 07/03/2025 |
| Singhal Priya SR OFF |
157.21 USD |
110 Sold |
17,293 USD |
06/12/2024 | 09/12/2024 |
| Singhal Priya SR OFF |
204.22 USD |
431 Sold |
88,019 USD |
30/08/2024 | 03/09/2024 |
| Singhal Priya SR OFF |
213.09 USD |
93 Sold |
19,817 USD |
02/04/2024 | 02/04/2024 |
| Singhal Priya SR OFF |
221.23 USD |
262 Sold |
57,962 USD |
22/02/2024 | 22/02/2024 |